Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results

Q: What Q4 2025 revenue did Penumbra (PEN) report preliminarily?

Penumbra reported preliminary Q4 2025 revenue of $383.0M–$384.8M, a ~21.4%–22.0% increase year‑over‑year.

Q: What is Penumbra's preliminary full‑year 2025 revenue and growth (PEN)?

Preliminary full‑year 2025 revenue was $1,401.3M–$1,403.1M, representing ~17.3%–17.5% growth versus 2024.

Q: How did the China region affect Penumbra's 2025 revenue growth (PEN)?

Excluding China, Penumbra's FY 2025 revenue growth was ~24.7%–24.9%, higher than the reported ~17.3%–17.5%.

Q: What gross margin did Penumbra report for FY 2025 (PEN)?

Penumbra reported a preliminary gross margin of 67.1% for full year 2025 and ~67.9%–68.1% for Q4 2025.

Q: What operating margins did Penumbra report for Q4 and FY 2025 (PEN)?

Preliminary operating margin was 14.8%–15.7% for Q4 2025 and 13.3%–13.6% for full year 2025.

Penumbra (NYSE: PEN) provided unaudited, preliminary results for Q4 and full year 2025.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Penumbra (NYSE: PEN) provided unaudited, preliminary results for Q4 and full year 2025. Q4 revenue is estimated at $383.0M–$384.8M (+21.4% to +22.0% YoY; +23.2% to +23.8% ex-China). Full-year revenue is estimated at $1,401.3M–$1,403.1M (+17.3% to +17.5% YoY; +24.7% to +24.9% ex-China). Gross margin is ~67.9%–68.1% for Q4 and 67.1% for FY2025. Income from operations is $56.9M–$60.4M (Q4) and $186.9M–$190.4M (FY), implying operating margins of 14.8%–15.7% (Q4) and 13.3%–13.6% (FY).

Positive

Q4 revenue +21.4% to +22.0% YoY ($383.0M–$384.8M)
FY 2025 revenue $1,401.3M–$1,403.1M (+17.3% to +17.5% YoY)
Ex-China FY revenue growth ~24.7% to 24.9%
FY operating income $186.9M–$190.4M (operating margin 13.3%–13.6%)

Negative

Reported FY growth reduced to 17.3%–17.5% due to China region impact
Results are unaudited and preliminary pending final audit

Argus Jan 15 session

+11.82% close to close Open Argus

Details

News Market Reaction – PEN

In the Jan 15 session, PEN gained 11.82%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +11.8% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +11.8% in the session following this news. A strong positive reaction aligns with preliminary 2025 results showing robust revenue growth and margins, such as Q4 revenue of $383.0M–$384.8M and gross margin near 68%. Historical data show mixed short-term trading after good news, so investors might have weighed prior tendencies to sell into strength against the confirmation that full‑year revenue exceeded earlier guidance and operating margins reached the mid‑teens.

Key Figures

Q4 2025 revenue: $383.0M–$384.8M Q4 revenue growth: 21.4%–22.0% Q4 ex-China growth: 23.2%–23.8% +5 more

Q4 2025 revenue: $383.0M–$384.8M; Unaudited preliminary Q4 2025 revenue vs Q4 2024
Q4 revenue growth: 21.4%–22.0%; Year-over-year growth vs Q4 2024
Q4 ex-China growth: 23.2%–23.8%; Q4 2025 revenue growth excluding China region
FY 2025 revenue: $1,401.3M–$1,403.1M; Unaudited preliminary full year 2025 revenue
FY revenue growth: 17.3%–17.5%; Year-over-year revenue growth vs full year 2024
FY ex-China growth: 24.7%–24.9%; Full year 2025 revenue growth excluding China region
Q4 gross margin: 67.9%–68.1%; Unaudited preliminary gross margin for Q4 2025
FY operating income: $186.9M–$190.4M; Full year 2025 income from operations; 13.3%–13.6% margin

Historical Context

5 past events · Latest: Dec 29

5 events

Dec 29
Conference appearance

24h Move

-0.2%

Announcement of presentation at 44th J.P. Morgan Healthcare Conference.
Nov 19
Conference appearance

24h Move

-1.2%

Planned presentation at Piper Sandler 37th Annual Healthcare Conference.
Nov 05
Quarterly earnings

24h Move

-4.1%

Q3 2025 revenue growth with higher guidance and solid margins.
Nov 03
Clinical trial data

24h Move

-0.5%

STORM-PE trial showed superior outcomes for CAVT plus anticoagulation.
Oct 27
Clinical trial data

24h Move

-2.0%

Landmark STORM-PE RCT demonstrated CAVT superiority over anticoagulation alone.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/15/2026 - 07:00 AM

ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the fourth quarter and full year 2025.

Unaudited and Preliminary Financial Highlights:

Fourth quarter 2025 revenue of $383.0 million to $384.8 million, which represents growth of approximately 21.4% to 22.0% compared to the fourth quarter of 2024. Excluding the impact of the China region, revenue growth was approximately 23.2% to 23.8% for the fourth quarter 2025.
Revenue of $1,401.3 million to $1,403.1 million for the full year 2025, which represents growth of approximately 17.3% to 17.5% compared to the full year 2024. Excluding the impact to the China region, revenue growth was approximately 24.7% to 24.9% for the full year 2025.
Gross margin of 67.9% to 68.1% for the fourth quarter 2025 and 67.1% for the full year 2025.
Income from operations of $56.9 million to $60.4 million or operating margin of 14.8% to 15.7% for the fourth quarter of 2025.
Income from operations of $186.9 million to $190.4 million or operating margin of 13.3% to 13.6% for the full year 2025.

About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

Investor Relations
Penumbra, Inc.
investors@penumbrainc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-provides-preliminary-update-on-fourth-quarter-and-full-year-2025-financial-results-302661933.html

SOURCE Penumbra, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Q4 2025 revenue did Penumbra (PEN) report preliminarily?

Penumbra reported preliminary Q4 2025 revenue of $383.0M–$384.8M, a ~21.4%–22.0% increase year‑over‑year.

What is Penumbra's preliminary full‑year 2025 revenue and growth (PEN)?

Preliminary full‑year 2025 revenue was $1,401.3M–$1,403.1M, representing ~17.3%–17.5% growth versus 2024.

How did the China region affect Penumbra's 2025 revenue growth (PEN)?

Excluding China, Penumbra's FY 2025 revenue growth was ~24.7%–24.9%, higher than the reported ~17.3%–17.5%.

What gross margin did Penumbra report for FY 2025 (PEN)?

Penumbra reported a preliminary gross margin of 67.1% for full year 2025 and ~67.9%–68.1% for Q4 2025.

What operating margins did Penumbra report for Q4 and FY 2025 (PEN)?

Preliminary operating margin was 14.8%–15.7% for Q4 2025 and 13.3%–13.6% for full year 2025.

Are Penumbra's January 15, 2026 results final (PEN)?

No; the figures reported on January 15, 2026 are unaudited and preliminary pending final audited results.

Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results